Results 201 to 210 of about 421,693 (309)
What's New? The CDK4/6 inhibitor ribociclib in combination with an endocrine‐based therapy has demonstrated significant progression‐free and overall survival benefits in patients with advanced/metastatic HR+/HER2‐ breast cancer in the pivotal MONALEESA trials.
Peter A. Fasching +20 more
wiley +1 more source
Metoclopramide-Induced Pheochromocytoma Crisis: A Case Report and Literature Review. [PDF]
Yamanashi Y +4 more
europepmc +1 more source
Abstract Autoimmune encephalitis is a group of disorders characterized by symptoms of dysfunction of the limbic and extra‐limbic systems that occur in association with antibodies against intracellular antigens, synapses, or proteins located on the surface of nerve cells. Anti‐NMDA (N‐methyl‐D‐aspartate) receptor encephalitis was first described in 2007
Pham Ba Nha +6 more
wiley +1 more source
Physical agents' level in women with primary dysmenorrhea: A cross‐sectional observational study
Abstract Objective Primary dysmenorrhea (PD), menstrual pain in the absence of pathology, is the main reason for gynecological consultation in young women. Physical agents, used in physiotherapy for therapeutic purposes, can be self‐used by women with primary dysmenorrhea.
Zeltia Naia, Olalla Bello
wiley +1 more source
The efficacy of rimegepant for the acute treatment of vestibular migraine. [PDF]
Chu H, Pan J, Huang C.
europepmc +1 more source
Abstract Objective In the dose‐escalation part of Study 101, which included multiple tumor types, objective responses were observed in 10 of 22 patients across multiple dose levels of farletuzumab ecteribulin (FZEC). We explored the safety/antitumor activity of FZEC in patients with platinum‐resistant ovarian cancer (PROC) from the Study 101 expansion ...
Kan Yonemori +11 more
wiley +1 more source
Addisonian Crisis in a 39-Year-Old Woman With Primary Adrenal Insufficiency. [PDF]
Itteera MR, Gutierrez M, Patel KH.
europepmc +1 more source

